Table Fazostabil n / v 75 + 15.2mg film 100 pcs

Description

Composition
Active substance:
1 tablet contains: Acetylsalicylic acid – 75.00 mg; Magnesium hydroxide – 15.20 mg. 1 tablet contains: Acetylsalicylic acid – 150.00 mg; Magnesium hydroxide – 30.39 mg.
Product form:
Tablets, film-coated, 75 mg + 15.2 mg and 150 mg + 30.39 mg. 10, 20, 25 or 30 tablets in blisters of PVC film and aluminum foil printed patent. One jar or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
Hypersensitivity, erosive and ulcerative lesions GIT (exacerbation), bleeding from the gastrointestinal tract, bronchial asthma induced by ASA et al. NSAIDs, cerebral hemorrhage, a tendency to bleed (hemorrhagic diathesis, thrombocytopenia, avitaminosis K), severe chronic renal failure (creatinine clearance less than 10 ml / min), deficiency of glucose-6-phosphate dehydrogenase, simultaneous with methotrexate at a dose of 15 mg / week, pregnancy (I and III trimester), lactation, children up to 18 years.
Carefully
Gout, hyperuricemia, erosive or ulcerative lesion gastrointestinal bleeding from the gastrointestinal tract in history, renal / hepatic failure, bronchial asthma, hay fever, polyps, nasal mucosa, allergic diseases, pregnancy (II trimester).
Dosage
75 mg + 15.2 mg
Indications
– Primary prevention of cardiovascular diseases such as thrombosis and congestive heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, old age). – prevention of reinfarction and thrombosis of blood vessels. – prevention of thromboembolism after surgical interventions on vessels (coronary artery bypass graft, percutaneous transluminal coronary angioplasty). – Unstable angina.
Interaction with other drugs
Potentiates the effect of methotrexate (by reducing renal clearance and displacement connection with protein), heparin anticoagulants (due to abnormalities of platelet function and displacement anticoagulants connection with protein), thrombolytic et al. Antiplatelet agents (ticlopidine), digoxin (reduces its renal excretion), valproic acid (due to repression of their connection to the protein), hypoglycemic drugs (sulfonylureas and insulin) hypoglycemic properties due to the very high doses of ASA and derivatives displacement sul fonilmocheviny connection with protein. At reception there is an additive effect of ethanol. Reduces the effect of uricosuric drugs (benzbromarone) due to competitive tubular excretion of uric acid. GCS enhancing elimination, weaken the effect. Antacids colestyramine and reduce the absorption of the drug.
Overdose
Symptoms of nausea, vomiting, tinnitus, hearing loss, dizziness, confusion. Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
Antiplatelet agent.
Pharmacological properties:
Underlying mechanism of action of acetylsalicylic acid (ASA) is irreversible inhibition of cyclooxygenase (COX-1), resulting in blocked synthesis of thromboxane A2 and platelet aggregation is suppressed. It is believed that ASA has other mechanisms of platelet aggregation suppressant that expands the scope of its application in various vascular diseases. ASA has also anti-inflammatory, analgesic, antipyretic effect. The anti-inflammatory effect is due to a decrease in blood flow due to inhibition of the synthesis of prostaglandin E2. Magnesium hydroxide, which is part of Fazostabil preparation has antacid effect and protects the mucous membrane of the gastrointestinal tract from the effects of ASA.
Pharmacodynamics:
Combination drug action is due to its constituent components. ASA – NSAID, blocking and TSOG1 TSOG2 synthesis gives Pg, anti-inflammatory, antipyretic and analgesic action, inhibits platelet aggregation. Analgesic effect is due to both central and peripheral action. It acts on the thermoregulatory center, reduces the temperature in febrile states. Decreases aggregation, thrombus formation and platelet adhesiveness by inhibiting thromboxane A2 synthesis in platelets. Magnesium hydroxide reduces the irritant effect on the gastric mucosa.
Conditions of supply of pharmacies
Without a prescription.
side effects
From the digestive system nausea, heartburn, vomiting, abdominal pain, mucous membrane of stomach ulcers and 12 duodenal ulcer, including with perforation and gastrointestinal bleeding, increased activity of “liver” transaminases, stomatitis, esophagitis, ulceration of the mucous membrane of the digestive tract of the lower divisions, strictures, colitis, bowel irritation. Bronchoconstriction of the respiratory system. From the side of hematopoiesis anemia (including aplastic), hypoprothrombinemia, thrombocytopenia, increased bleeding, neutropenia, eosinophilia, agranulocytosis. Nervous system dizziness, headache, insomnia, somnolence, tinnitus, intracranial hemorrhage. Allergic reactions urticaria, angioneurotic edema, anaphylaxis.
special instructions
ACK may be the cause of bleeding of varying severity during or after surgery. May provoke bronchospasm and also cause bronchial asthma attack, etc. Hypersensitivity reaction. Risk factors are the availability of a history of asthma, hay fever, nasal polyps, COPD, allergic reactions to others. NSAIDs. ASA at low doses reduce the excretion of uric acid. Patients with the predisposition it can in some cases trigger a gout attack. During treatment should abandon the use of ethanol (increased risk of gastrointestinal bleeding). ASA has a teratogenic effect, when used in the I trimester leads to congenital malformations – splitting the upper palate, in the III trimester – to inhibition of labor (inhibition of synthesis Pg), closure of ductus arteriosus in the fetus, causing hyperplasia of pulmonary vascular and hypertension in the vessels of the pulmonary circulation. Excreted in breast milk, which increases the risk of bleeding in a child due to dysfunction of platelets.
Dosing and Administration
Inside, tablets, film-coated, drug Fazostabil swallowed whole with water. Fazostabil drug for long-term treatment. Duration of treatment is determined by the doctor. – Primary prevention of cardiovascular diseases such as thrombosis and congestive heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, advanced age) 1 tablet Fazostabil preparation containing ASA in a dose of 150 mg in the first hours, followed by 1 tablet comprising ASA 75 mg 1 time per day. – prevention of reinfarction and thrombosis of blood vessels Fazostabil 1 tablet formulation containing ASA in doses of 75-150 mg 1 time per day. – prevention of thromboembolism after surgical interventions on vessels (coronary artery bypass graft, percutaneous transluminal coronary angioplasty) Fazostabil 1 tablet formulation containing ASA in a dose of 75 – 150 mg 1 time per day. – Unstable angina Fazostabil 1 tablet formulation containing ASA in a dose of 75 -150 mg 1 time per day. When skipping the next dose of the drug Fazostabil should take the missed dose as soon as the patient remembers it. To avoid doubling the dose should not take the missed pill when approaching the reception of the next dose. Features of action at the first admission or withdrawal of the drug were observed.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist